Register for our S/EIS Fund

Protac Services

We have expertise in the synthesis of PROTAC for targeted protein degradation and integrated drug discovery

Get a quote

PROTAC

(PROteolysis TArgeting Chimeras)

PROTAC ®, or targeted protein degradation using Proteolysis Targeting Chimeras, is a novel and promising therapeutic method in drug discovery. PROTACs have the ability to control protein degradation by targeting ubiquitin E3 ligases.

At o2h discovery, we have strong expertise in the synthesis of PROTACs and related chemistry, providing comprehensive solutions for PROTAC building blocks, linkers, compound libraries, and related intermediates to support Targeted Protein Degradation and integrated drug discovery programs.

Know more

Listen to what our client says about our protac services

- Julian Blagg, Executive VP, Drug Discovery
- Martin Drysdale, Chief Scientific Officer

about o2h discovery

o2h discovery has an integrated drug discovery platform operating from its state-of-the-art research centres in Ahmedabad, India, and The Mill Scitech Park, Cambridge, UK.

o2h discovery is a highly reputed service provider of mg/g scale discovery chemistry. We have partnered with a range of well-known pharmaceutical and biotechnology companies from Europe, the USA, and Japan.

our services

A premier Contract Research Organisation providing integrated and biology services for collaborative research

our team

Sunil Shah

Co-founder, o2h group

Sunil Shah

Sunil Shah

Co-founder, o2h group

A serial entrepreneur having begun a career in the Life Sciences team at PA Consulting group followed by co-founding two companies in the information technology and life sciences sector. The second of these companies, Oxygen Healthcare Ltd was acquired by Piramal Enterprises Ltd (BSE: PEL). Sunil is the Chairman of Exonate and a board member of Cambridge Angels, Biotech Industry Association, and advisory board of the DBT & CRUK affordable cancer medicines initiative. Sunil has a degree in Biochemistry from Keele and an MBA from Cambridge University.

Connect on Linkedin

Prashant Shah

Co-CEO and Co-Founder, o2h group

Prashant Shah

Prashant Shah

Co-CEO and Co-Founder, o2h group

A serial entrepreneur having begun a career with the Strategy group of at Accenture followed by co-founding two companies in the technology and life sciences sector. The second of these companies focused on drug discovery was acquired by a public company. Prashant co-founded o2h Ventures which is involved in seeding, incubating and investing in early stage life science and technology companies. Prashant has a BEng, MSc and an MPhil in Management.

Connect on Linkedin

Andy Morley

Chief Scientific Officer, o2h discovery

Andy Morley

Andy Morley

Chief Scientific Officer, o2h discovery

Creative and innovative medicinal chemist with extensive knowledge and expertise. Twenty five years experience working in the pharmaceutical industry.

Connect on Linkedin

Nilesh Dagia

Special Projects, o2h group

Nilesh Dagia

Nilesh Dagia

Special Projects, o2h group

Nilesh leads the global operations of o2h group covering a wide range of innovation led investment, life-science and technology businesses. He is also overseeing the development and execution of the new o2h discovery Shirish Research Centre in Ahmedabad, India. Prior to joining o2h group, Nilesh worked with Piramal Group in various capacities including as an Alliance Manager for a risk-share oncology-based collaboration with a US Big Pharma and has also worked as the Head of Biology in Piramal Discovery solutions. Nilesh obtained his Ph.D. from Ohio University and completed a post-doc in Immunology, Stem Cells and Regenerative Medicine at Harvard Medical School. He is the author and inventor of >30 life science patents and publications. He received the Young Scientist of India award from OPPI in 2010.

Connect on Linkedin

Gayathri Sadasivam

Head of Biology, o2h discovery

Gayathri Sadasivam

Gayathri Sadasivam

Head of Biology, o2h discovery

Gayathri leads the biology capabilities in Ahmedabad, India and Cambridge, UK. She also significantly contributes to the business development with the o2h customers world-wide, understanding the market requirements, contributing to technology transfer and investment evaluations. Prior to this, she has worked for >15 years in different therapeutic areas in both industry and academia. She has led multiple programs in drug discovery projects through lead optimization to candidate selection and further development to late stage clinical trials. She has worked in a multi-disciplinary environment, leading chemical biology efforts creating chemical tools that modulate novel class of “undruggable” targets. Gayathri has a Ph.D. in Neuroscience from the Brain Research Institute, Zurich, Switzerland.

Connect on Linkedin

Claudio Dagostin

Director, Business Development, o2h discovery

Claudio Dagostin

Claudio Dagostin

Director, Business Development, o2h discovery

Claudio got his PhD in Chemistry (Mechanisms of Organic Reactions) from the University in 2000. He went for a post-doc at Imperial College London where he worked on Alzheimer's disease chemical probes. In 2004, he started working in several companies in the Cambridge biotech cluster where he deepened his knowledge in Medicinal Chemistry and in Fragment Based Drug Design. In 2012 he went back to academia at Cambridge University where he investigated challenging drug targets such as protein-protein interactions. He also co-founded the Entrepreneurial Postdocs of Cambridge (EPOC) society in 2015 to support postdocs in their pursuit of entrepreneurial careers. In 2017 joined Capital Cell and then Abzena in Cambridge with a role in Business Development.

Connect on Linkedin

Hemal Soni

Head of Chemistry, o2h discovery

Hemal Soni

Hemal Soni

Head of Chemistry, o2h discovery

Comprehensive experience in Leading & Guiding Multi-FTE “Synthetic Chemistry Research” Collaborations which are in support to fast paced Medicinal Chemistry Projects – for overseas collaborators.

Connect on Linkedin

Vinkal Zalavadia

Analytical lead, o2h discovery

Vinkal Zalavadia

Vinkal Zalavadia

Analytical lead, o2h discovery

Vinkal has obtained his Master degree in Analytical Chemistry 2007 from S.P university. He has industrial experience >15 years during which he has served many MNC like Alembic, Torrent, Piramal etc. He started his career with o2h in 2007 as fresher and worked for 3 year and moved to other organisation. He re-joined the o2h family back in 2021 and has been with us since then. During his professional tenure, Vinkal has leading method development group, purification and isolation group and he has immense expertise in purification and characterization of heterocyclic, macrocylic, natural product etc. in nature. He has been for several years leading a big team of Analytical chemists (currently >70) who skilfully operates instruments like LCMS, HPLC, SFC, NMR and Preparative HPLC under his guidance.

Connect on Linkedin

Speak to a member of our team